Alma, which makes software program and assist instruments for psychological well being professionals constructing their practices, raised $130 million in Sequence D funding. The spherical comes a couple of yr after the corporate introduced its $50 million Series C.
The spherical was led by Thoma Bravo, with participation from Cigna Ventures, Perception Companions, Optum Ventures, Tusk Enterprise Companions, Major Enterprise Companions and Sound Ventures. Alma mentioned its whole elevate is now greater than $220 million.
The startup presents teletherapy software program, billing and scheduling instruments and a group of different psychological healthcare professionals in addition to a listing to assist sufferers discover in-network suppliers.
“By centering therapists on the forefront, Alma is making a sustainable enterprise mannequin that helps suppliers settle for insurance coverage, develop their non-public apply, and attain extra folks looking for care. Over the previous yr, we scaled our providers to supply in-network psychological well being care in all 50 U.S. states, serving to folks discover much-needed care throughout their best moments of want,” Alma founder and CEO Dr. Harry Ritter mentioned in a press release.
Truthful Sq. Medicare, a tech-enabled insurance coverage navigator, introduced Thursday it had raised $15 million in Sequence A funding.
The spherical was led by Outline Ventures, with participation from Sluggish Ventures, YCombinator and angel buyers, and introduced the startup’s whole elevate to $19 million.
With the funding, Truthful Sq. Medicare plans to launch new providers, together with serving to seniors discover and schedule appointments with suppliers, organising preventative well being and dental care, discovering lower-cost prescription choices and accessing digital continual care administration packages.
“Seniors deserve a trusted healthcare accomplice that is at all times performing of their greatest curiosity,” Chirag Shah, accomplice at Outline Ventures, mentioned in a press release. “Truthful Sq. Medicare’s mannequin builds belief with seniors, as a result of it treats them like household. If you prioritize the long-term relationship with the shopper over potential short-term monetary positive factors, they’re going to belief you with extra of their well being. That is the recipe for sustainable progress, which is why we’re investing in Truthful Sq. Medicare’s future.”
Avenda Well being, which is creating an AI platform to higher visualize prostate most cancers, scored $10 million in a Sequence B funding spherical led by VCapital.
Different members within the elevate embody Plug & Play Ventures and Wealthing VC Membership. The startup plans to make use of the capital to hurry using iQuest, its investigational software program goals to visualise most cancers for higher remedy planning.
“Our firm’s mission is to supply clinicians and their sufferers better entry to care whereas sustaining high quality of life that’s usually lacking in prostate most cancers remedy. Our know-how is fixing key points in males’s well being and we stay up for creating actual change in prostate most cancers care,” Avenda CEO and cofounder Dr. Shyam Natarajan mentioned in a press release. “This funding will play a important position in increasing the potential and attain of our know-how, whereas including to our skilled crew of urology, medical gadget and AI leaders.”
Oncology medical trial startup Trial Library emerged from stealth earlier this week with $5 million in seed funding.
The spherical was led by Deena Shakir, accomplice at Lux Capital, with participation from Julian Eison, managing accomplice at NEXT VENTŪRES, Unseen Capital and different angel buyers.
The corporate presents reimbursement to native suppliers and oncology practices for pre-screening and referring sufferers to medical trials. It additionally supplies navigators for sufferers trying to enroll, directing them to journey, meals and logistics assets.
“The dearth of fairness in entry is a large barrier that must be solved,” CEO and founder Dr. Hala Borno mentioned in a press release. “As a society, we have invested a lot into thrilling new biotech therapies and we’re optimistic that many of those customized therapies will lengthen sufferers’ lives. Nonetheless, there are nonetheless many obstacles that exist, and we goal to fight the obstacles skilled by all members in our analysis ecosystem – the sufferers, suppliers and researchers.”
